Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Radical cystectomy
7 evidence topics · 9 sources
Guideline recommendation: radical cystectomy as the standard option for BCG-unresponsive disease
Standard of care, morbidity, and deferral of surgery
“Standard treatment for patients with BCG-unresponsive NMIBC is radical cystectomy, which carries substantial morbidity and mortality; the incidence of complications is 35% to 40% and the 90-day mortality rate is 4.7%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Major guidelines recommend radical cystectomy (RC) with urinary diversion as the standard‐of‐care for BCG‐unresponsive NMIBC due to higher propensity for disease recurrence and progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer‐specific survival (CSS) is >80% after RC is performed for NMIBC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, many patients defer RC due to concerns about perioperative morbidity and its impact on quality of life (QoL).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although radical cystectomy is the preferred treatment for BCG-unresponsive disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“surgery is associated with considerable morbidity and mortality risks, which are particularly germane for patients with this disease, who are often older and have comorbid conditions” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Upfront radical cystectomy compared with bladder-sparing therapy: multicenter retrospective cohort
“Among 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow‐up was 50 (20–69) months. There were no statistically significant differences in metastasis‐free survival, cancer‐specific survival, or overall survival between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no significant differences in MFS (HR 0.88, 95% CI 0.53–1.46; P = 0.62), CSS (HR 0.91, 95% CI 0.54–1.53; P = 0.73), or OS (HR 1.31, 95% CI 0.91–1.90; P = 0.15) between patients who received upfront RC compared to those receiving BST at time of diagnosis of BCG‐unresponsive NMIBC (Fig. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although adverse oncological outcomes began to rise 12 months after diagnosis, the rate of dying from bladder cancer were similar at 14% in both the upfront RC and BST groups at 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The low rates of metastasis and death for patients who underwent BST are reassuring, but comparison with RC is impacted by selection bias.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radical cystectomy compared with bladder-sparing therapy: prospective CISTO cohort, 12-month results
“Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among participants who selected RC, 15 (8.0%) experienced prolonged hospitalization after their RC, 57 (30%) were readmitted within 90 days, and five (2.5%) died within 90 days” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upstaging occurred among 22% of patients undergoing RC, reflective of the higher cancer severity in the RC arm and well-established understaging of bladder cancer with imaging and endoscopy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Timing of radical cystectomy after BCG failure
“Five-year overall and cancer specific survival was similar in groups 1 and 2 at 80% and 85%, respectively, at approximately equivalent followups. Median bladder retention was 1.7 years longer in group 2 (p <0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“On multivariate Cox regression analysis delayed cystectomy in group 2 did not convey a significant hazard for all cause mortality after cystectomy (HR 1.08, p = 0.808).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the historical cohort the 85 patients with documented T1 recurrence were initially treated with repeat transurethral resection and intravesical bacillus Calmette-Guerin.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 5 years after T1 recurrence, the cumulative incidence of progression to T2 disease was 71% (95% CI 61%, 81%) and the cumulative incidence of death from disease was 48% (95% CI 39%, 60%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In this cohort 65 of the 129 patients with recurrent T1 underwent immediate radical cystectomy. At 5 years after T1 recurrence, the cumulative incidence of progression to muscle invasive disease was 28% (95% CI 20%, 38%) and the cumulative incidence of death from disease was 31% (95% CI 22%, 42%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Early complications of radical cystectomy: standardized reporting in 1,142 procedures
“Sixty-four percent (735/1142) of patients experienced a complication within 90 d of surgery.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, the highest grade of complication was grade 0 in 36% (n=407), grade 1-2 in 51% (n=582), and grade 3-5 in 13% (n=153). Gastrointestinal complications were most common (29%), followed by infectious complications (25%) and wound-related complications (15%). The 30-d mortality rate was 1.5%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Ninety-day mortality after radical cystectomy: muscle-invasive disease, National Cancer Database
“Among 7922 patients, 90-day mortality was 7.6% (8.0% for lower and 6.7% for higher volume hospitals).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The model predicted 25% of patients had a 90-day mortality risk higher than 10%, and observed 90-day mortality in this group was 14.0% (95% CI = 12.5% to 15.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote